Valuation: Aclarion, Inc.

Market Cap 6.5M 5.68M 5.25M 4.82M 9.13M 626M 9.28M 62.67M 24.62M 306M 24.41M 23.88M 1.06B P/E 2026 *
-0.59x
P/E 2027 * -0.48x
Enterprise Value 6.5M 5.68M 5.25M 4.82M 9.13M 626M 9.28M 62.67M 24.62M 306M 24.41M 23.88M 1.06B EV / Sales 2026 *
48.2x
EV / Sales 2027 * 25.3x
Free-Float
73.8%
Yield 2026 *
-
Yield 2027 * -
1 day-0.75%
1 week-9.28%
Current month-8.33%
1 month-10.20%
3 months-20.48%
6 months-30.34%
Current year-42.61%
1 week 2.59
Extreme 2.59
2.88
1 month 2.59
Extreme 2.59
3.24
Current year 2.34
Extreme 2.3401
9.36
1 year 2.34
Extreme 2.3401
12.03
3 years 2.34
Extreme 2.3401
104,053.6
5 years 2.34
Extreme 2.3401
586,115.57
10 years 2.34
Extreme 2.3401
586,115.57
Manager TitleAgeSince
Chief Executive Officer 59 2021-09-14
Director of Finance/CFO 60 2025-09-01
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member 69 2015-12-31
Director/Board Member 55 2016-08-31
Chairman 61 2022-04-20
Date Insider Type Main position Quantity % Market Cap.
6/11/26 Free

Director

20,000 0.8123%
6/11/26 Free

Director

20,000 0.8123%
6/11/26 Free

Chairman

100,000 4.0613%
Change 5-day change 1-year change 3-year change Capi.($)
-0.75%-9.28%-64.32%-100.00% 6.55M
-1.07%-1.27%+0.95%+5.66% 50.35B
-2.85%-6.25%+366.61%+572.09% 39.21B
+1.78%+0.73%+32.68%-4.80% 34.52B
+1.98%+4.82%+13.71%+61.68% 34.6B
+0.06%+1.56%+4.41%+27.42% 27.05B
-3.27%-5.67% - - 16.68B
+1.64%+0.45%+70.86%+121.18% 15.11B
+0.29%+1.02%+14.95%+17.80% 13.85B
-1.21%+0.73%+18.02%-30.96% 13.18B
Average -0.34%-0.82%+50.87%+74.45% 24.46B
Weighted average by Cap. -0.31%+0.41%+77.50%+118.91%

Financials

2026 *2027 *
Net sales 135K 118K 109K 100K 190K 13.01M 193K 1.3M 511K 6.35M 507K 496K 21.93M 257K 225K 208K 191K 361K 24.76M 367K 2.48M 973K 12.09M 965K 944K 41.75M
Net income -10.71M -9.36M -8.66M -7.94M -15.03M -1.03B -15.29M -103M -40.55M -504M -40.21M -39.33M -1.74B -13.47M -11.77M -10.89M -9.99M -18.91M -1.3B -19.23M -130M -51M -634M -50.57M -49.46M -2.19B
Net Debt - -
Logo Aclarion, Inc.
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Employees
11
Date Price Change Volume
26-07-16 US$2.640 -0.75% 34,213
26-07-15 US$2.660 -0.37% 25,007
26-07-14 US$2.670 -0.74% 36,544
26-07-13 US$2.690 -5.41% 61,035
26-07-10 US$2.844 -2.27% 20,021
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.640USD
Average target price
7.500USD
Spread / Average Target
+184.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACON Stock